MAP3K7 and acute lymphoblastic leukemia: There was a trend for SIL-TAL1 positive T-ALL patients harboring a MAP3K7/CASP8AP2 deletion towards a higher risk of relapse compared to patients with SIL-TAL1 fusion, but without MAP3K7/CASP8AP2 deletion (p(Gray) = 0.13; Fig. 2b).